Eylea and the newer Eylea HD are both injectable medications used to treat certain serious eye conditions caused by abnormal blood vessel growth or leakage. The main difference between the two ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...

With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is racing to carve out a new market for the high-dose version of its ...

Please provide your email address to receive an email when new articles are posted on . Eylea HD allowed for longer treatment intervals compared with Eylea and showed similar safety and efficacy.

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) ...